Serum Anti‐LRPAP1 is a Common Biomarker for Digestive Organ Cancers and Atherosclerotic Diseases

Serum Anti‐LRPAP1 is a Common Biomarker for Digestive Organ Cancers and Atherosclerotic Diseases:

Abstract

Some cancers are related to atherosclerotic diseases, therefore these two types of disease may share some antibody biomarkers in common. To investigate this, a first screening was performed of sera from patients with esophageal squamous cell carcinoma (ESCC) or acute ischemic stroke (AIS) for serological identification of antigens using recombinant cDNA expression cloning (SEREX). The amplified luminescent proximity homogeneous assay‐linked immunosorbent assay (AlphaLISA) method, which incorporates glutathione‐donor beads and anti‐human‐IgG‐acceptor beads, was used to evaluate serum antibody levels. SEREX screening identified low‐density lipoprotein receptor‐related protein‐associated protein 1 (LRPAP1) as a target antigen of serum IgG antibodies in the sera of patients with ESCC or AIS. Antigens, including recombinant glutathione S‐transferase (GST)‐fused LRPAP1 protein, were prepared to examine serum antibody levels. AlphaLISA revealed significantly higher antibody levels against the LRPAP1 protein in patients with solid cancers such as ESCC and colorectal carcinoma and some atherosclerosis‐related diseases such as AIS and diabetes mellitus compared with healthy donors. Correlation analysis revealed that the elevated serum antibody levels against LRPAP1 were associated with smoking, a well‐known risk factor for both cancer and atherosclerosis. Serum LRPAP1 antibody is therefore a common marker for the early diagnosis of some cancers and atherosclerotic diseases and may reflect diseases caused by habitual smoking.